share_log

Maxim Group Upgrades Vistagen Therapeutics to Buy, Announces $30 Price Target

Benzinga ·  Aug 7, 2023 19:09

Maxim Group analyst Jason McCarthy upgrades Vistagen Therapeutics (NASDAQ:VTGN) from Hold to Buy and announces $30 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment